AbbVie, a research-based global biopharmaceutical company, has announced that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
"We are pleased to reach this important milestone for the company, its employees, shareholders and the patients we serve," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Our new Allergan colleagues should be commended for all their efforts, along with those of our own employees, to achieve this turning point for our company. The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us. I am proud of both organizations and look forward to the opportunities ahead."

Read more at PR Newswire >>